The bone anabolic carotenoids p-hydroxycinnamic acid and 
ß-cryptoxanthin antagonize NF-κB activation in
MC3T3 preosteoblasts

MASAYOSHI YAMAGUCHI and M. NEALE WEITZMANN
Division of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University, Atlanta, GA 30322-0001, USA

Received December 11, 2008; Accepted February 17, 2009

DOI: 10.3892/mmr_00000150

Abstract. The carotene p-hydroxycinnamic acid and the xanthophyll ß-cryptoxanthin are members of the carotenoid family of plant-derived pigments, which are endowed with anti-osteoporotic properties in vivo. p-Hydroxycinnamic acid and ß-cryptoxanthin have been demonstrated to stimulate osteoblastic bone formation while simultaneously repressing osteoclastic bone resorption in vitro. However, their mechanisms of action remain poorly elucidated. It is well established that the NF-κB signal transduction pathway plays a critical role in osteoclast differentiation. Moreover, we recently demonstrated that NF-κB activity potently antagonizes osteoclastic differentiation and mineralization in vitro. In this study, we used transient transfection assays of a NF-κB luciferase reporter to demonstrate that p-hydroxycinnamic acid and ß-cryptoxanthin antagonize NF-κB activation in MC3T3 preosteoblastic cells. The data obtained suggest that NF-κB may be a common molecular target by which several bone active agents, including carotenoids, promote osteoblastic bone formation.

Introduction

Bone homeostasis is maintained by a delicate balance between osteoblastic bone formation and osteoclastic bone resorption. Numerous pathological processes have the capacity to disrupt this equilibrium, leading to conditions where the rate of bone resorption surpasses the rate of bone formation. The result is osteoporosis, a devastating bone disease that is widely recognized as a significant public health threat. Post-menopausal osteoporosis is the archetypal osteoporotic condition in women who have passed through menopause, and leads to bone destruction through complex and diverse metabolic and biochemical changes (1).

Pharmacologic and nutritional factors are associated with reduced postmenopausal bone loss, as chemical compounds present in certain foods appear to modulate bone turnover. Isoflavones such as genistein, found in high concentrations in soybeans, have been extensively studied for their estrogen-like properties and their capacity to stimulate bone formation (2) and suppress bone resorption (3,4). However, another group of bioactive phytochemicals, known as carotenoids, also appears to have bone active properties. Found predominantly in fruit and vegetables, carotenoids comprise both carotenes, such as ß-carotene, and ß-cryptoxanthin (CRP), lutein, lycopene and ß-carotene. Of note, CRP and HCA have anabolic effects on osteoblastic bone formation (5,6) and suppressive effects on osteoclastic bone resorption in vitro (5,7). Furthermore, oral administration of CRP (8) and HCA (9) ameliorated the bone loss induced by ovarioectomy in rats, in an animal model of postmenopausal osteoporosis. However, the molecular mechanism(s) by which these factors regulate bone homeostasis remain to be elucidated.

The NF-κB signal transduction pathway is critical for osteoclast development and function (10,11). For example, the double knockout of p50 and p52 NF-κB subunits in mice leads to osteopetrosis due to a severe defect in osteoclast differentiation (12). Furthermore, suppression of NF-κB signaling in vitro blocks osteoclast activation (13). Recently, we demonstrated the utility of pharmacological NF-κB suppression in inhibiting osteoclastic bone loss in ovariectomized mice (14). In a study on multiple myeloma-induced bone loss in vitro (15), and in an animal model of rheumatoid arthritis in vivo (16), it was similarly demonstrated that NF-κB modulation is an effective form of therapy.

We recently reported that NF-κB signaling represses basal osteoblast differentiation and mineralization in MC3T3 cells and antagonizes TGFß and BMP-2-mediated MC3T3 mineralization by downregulating SMAD activation (17). Other studies have found that NF-κB signaling antagonizes Smad activation in Saos2 osteosarcoma cells by a mechanism involving the induction of inhibitory Smad7 (18).

In this study, we demonstrated that HCA and CRP have the capacity to suppress NF-κB activity in MC3T3 preosteoblastic cells. HCA, but not CRP, was further found to repress TNFα-

Correspondence to: Dr Masayoshi Yamaguchi, Division of Endocrinology and Metabolism and Lipids, Department of Medicine, Emory University School of Medicine, 101 Woodruff Circle, 1329 WMBR, Atlanta, GA 30322-0001, USA
E-mail: yamamasa1155@yahoo.co.jp

Key words: p-hydroxycinnamic acid, ß-cryptoxanthin, NF-κB promoter, osteoblast, bone formation, osteoporosis
induced NF-κB signaling. These data suggest that the antagonism of NF-κB signaling may be a common mechanism by which anti-osteoporotic carotenoids promote bone formation or offer protection from the inflammatory inhibitors of bone formation, such as TNFa.

Materials and methods

Materials. α-minimal essential medium (α-MEM) and antibiotics (penicillin and streptomycin) were purchased from Invitrogen (Carlsbad, CA). Fetal bovine serum (FBS) was from Hyclone (Logan, UT). β-cryptoxanthin was obtained from Extrasynthese (Lyon-Nord, France). p-Hydroxycinnamic acid was purchased from Wako Pure Chemical Industries (Osaka, Japan). All other chemicals were obtained from the Sigma Chemical Corporation (St. Louis, MO) unless otherwise stated.

Cell culture. The preosteoblastic cell line MC3T3-E1, clone 14 (MC3T3) was purchased from the American Type Culture Collection (Manassas, VA) and has previously been described in detail (19). Cells were cultured at 37°C in a humidified 5% CO₂ incubator in plastic dishes containing α-MEM supplemented with 10% FBS, with 2 mM glutamine, 100 IU/ml penicillin and 100 μg/ml streptomycin. Cells were passaged every 3 days using 0.2% trypsin plus 0.02% EDTA in Ca²⁺/Mg²⁺-free phosphate-buffered saline (PBS).

NF-κB reporter constructs and luciferase assays. The NF-κB responsive reporter pNF-κB-LUC was purchased from BD Biosciences. Reporter plasmids (pNF-κB-LUC) or empty vector controls (pGL3-Basic) were transfected into MC3T3 cells using Lipofectamine 2000 reagent (Invitrogen) as vector controls (pGL3-Basic) were transfected into MC3T3 cells using Lipofectamine 2000 reagent (Invitrogen) as previously described (17). Briefly, MC3T3 cells (1x10⁵ cells/well) were cultured in 96-well white opaque luminometer plates (Corning Costar, Lowell, MA) for 24 h in α-MEM. Subsequently, the cells were changed to α-MEM without FBS and antibiotics, and transfected with pNF-κB-LUC reporter plasmid or empty vector. After 5 h, the medium was changed to α-MEM containing antibiotics, with or without 10% FBS. Wells were treated with vehicle, HCA (10⁻⁷ to 10⁻⁵ M) or CRP (10⁻⁶ or 10⁻⁵ M), and/or TNF-α (10 ng/ml), for 24 h. Luciferase activity was measured on a microplate luminometer (Turner Designs, Sunnyvale, CA, USA) following cell lysis in Passive Lysis Buffer (Promega, Madison, WI). Equal transfection efficiency was validated for all plasmids using Renilla luciferase reporter plasmid pRL-SV40 (Promega).

Statistical analysis. Statistical significance was determined using GraphPad InStat version 3 for Windows XP (GraphPad Software). Multiple comparisons were performed by one-way ANOVA with the Tukey-Kramer post test. P<0.05 was considered statistically significant. Data are presented as the mean ± SD of five replicate assays. Data are representative of two or more independent experiments.
of TNFα are a potent suppressor of bone formation and lower attainable peak bone mass in vivo under basal conditions (17). TNFα is also a well-known inflammatory cytokine that promotes bone destruction under pathological conditions such as estrogen deficiency, as well as in rheumatoid arthritis, by stimulating osteoclastic bone resorption and repressing bone formation (1,20). TNFα is a potent inhibitor of osteoblast differentiation and mineralization in vitro, an effect predominantly mediated through NF-κB signaling (17,21). Consequently, we examined the effect of HCA and CRP on TNFα-induced NF-κB activity. It was found that HCA potently and dose-dependently (10⁻⁶ to 10⁻⁵ M) inhibited TNFα-induced NF-κB activation (Fig. 3A). Interestingly, CRP had no significant effect on TNFα-induced NF-κB activity (Fig. 3B), suggesting a different site of action in the NF-κB pathway than that of HCA.

Discussion

It has been established that the carotenoids CRP and HCA mediate anti-osteoporotic properties in vivo (8,9). These two factors have the capacity to stimulate bone formation in vivo and to promote osteoblastic differentiation and mineralization in vitro (5-7). However, the mechanisms by which these anabolic actions are achieved are unclear. In this study, we demonstrated that the NF-κB signal transduction pathway, which antagonizes osteoblastic differentiation and function, is significantly suppressed by the two factors, thereby providing a potential partial explanation for their anabolic actions. TNFα is an inflammatory cytokine that antagonizes bone formation in vivo and osteoblastic differentiation in vitro. These effects are largely mediated through NF-κB signaling. Inflammatory levels of TNFα are known to impact bone formation. However, we recently reported that basal TNFα levels in vivo also dramatically lower the basal bone formation rate. We therefore speculated that HCA and CRP may promote the accumulation of basal bone mass and forestall bone loss during osteoporotic states, in part by antagonizing TNFα-induced NF-κB. Interestingly, only the carotenoid HCA was found to significantly reduce TNFα-induced NF-κB activity. In contrast, CRP, which was capable of regulating basal NF-κB activity, had no effect on TNFα-induced NF-κB. The reason for the difference in response between the two carotenoids remains unclear. However, given the diverse nature of the NF-κB signaling pathway, it is possible that these agents regulate different NF-κB species or pathways. The five members of the mammalian NF-κB family, RelA/p65, RelB, c-Rel, NF-κB1/p50 and NF-κB2/p52, are activated through one of
two specific pathways: the canonical NF-κB pathway or an alternative pathway. In the canonical pathway, activation of the inhibitor of IκB kinase (IKK) complex leads to the phosphorylation of NF-κB-associated IκBα. This catalyzes IκBα ubiquitination and proteasomal degradation and, in the process, releases active NF-κB dimers that translocate to the nucleus and enhance the transcription of target genes. In the alternative NF-κB pathway, NF-κB-inducing kinase (NIK) and IκKα target p100 for proteolytic processing, thereby releasing active RelB-containing dimers (22). The differential regulation of the two pathways by HCA and CRP provides a possible explanation for the differences observed in TNFα-induced NF-κB activation.

FBS contains a large number of poorly characterized growth factors and cytokines, proteins, and bioactive molecules that can dramatically alter cell function. Interestingly, our data demonstrate that factors contained in FBS have a suppressive effect on basal NF-κB activation. The relevance of this phenomenon in vivo remains unclear. Moreover, whether this factor is present in neonatal or adult serum is presently unknown. However, it worth noting that NF-κB is a significant initiator of inflammatory and immunological responses. During pregnancy, tolerance is essential to prevent fetal rejection. However, the mechanisms for maintaining tolerance are multifactorial and poorly understood (23). Nonetheless, it can be speculated that fetal production of an immunological suppressor that antagonizes maternal host NF-κB activation could play a role in desensitizing the maternal immune response to fetal antigens.

In conclusion, our data suggest that NF-κB antagonism may be a common mechanism by which several diverse bone anabolic agents act to stimulate osteoblast differentiation and activity. Some of these agents may also act to suppress TNFα-induced NF-κB, while others may target basal NF-κB levels. The identification of further novel NF-κB antagonists may be an important strategy for the future development of bone anabolic agents.

Acknowledgements

This study was supported in part by a grant from the University Research Committee of Emory University. M.N.W. is supported in part by grants from NIAMS (AR053607 and AR056090).

References